

## STATUS OF CLAIMS

### IN THE CLAIMS:

1. (Currently Amended). A method for treating gastric acid disorders comprising the step of administering to a patient suffering from a gastric acid disorder, in need of such treatment a therapeutically effective amount of at least one non-enteric coated proton pump inhibitor in a pharmaceutically acceptable carrier;

wherein said pharmaceutically acceptable carrier comprises an equimolar ratio of a bicarbonate salt of a Group IA metals and a carbonate salt of a Group IA metal where the Group IA metals is chosen from the Periodic Table of Elements.

2. (Original). The method of claim 1 wherein said Group IA metal of said bicarbonate salt is sodium.

3. (Original). The method of claim 1 wherein said Group IA metal of said carbonate salt is sodium.

4. (Original). The method of claim 1 wherein said Group IA metal of said bicarbonate salt is potassium.

5. (Original). The method of claim 1 wherein said Group IA metal of said carbonate salt is potassium.

6. (Original). The method of claim 1 wherein said non-enteric coated proton pump inhibitor is a substituted benzimidazole or pharmaceutically acceptable salt thereof.

7. (Original). The method of claim 6 wherein said substituted benzimidazole is lansoprazole or a pharmaceutically acceptable salt thereof.

8. (Cancelled).

9. (Original). The method of claim 2 wherein said bicarbonate salt of said Group IA metal is sodium bicarbonate.
10. (Original). The method of claim 3 wherein said carbonate salt of said Group IA metal is sodium carbonate.
11. (Original). The method of claim 9 wherein said pharmaceutically acceptable carrier contains from about 125mg to about 1000mg of sodium bicarbonate.
12. (Original). The method claim of claim 10 wherein said pharmaceutically acceptable carrier contains from about 125mg to about 1000mg sodium carbonate.
13. (Currently Amended). A method for treating gastric acid disorders comprising the step of administering to a patient suffering from a gastric disorder, in need of such treatment a therapeutically effective amount of non-enteric coated lansoprazole or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier;  
wherein said pharmaceutically acceptable carrier comprises an equimolar ratio of sodium carbonate to sodium bicarbonate.
14. (Original). The method of claim 13 wherein said pharmaceutically acceptable carrier contains from about 125mg to about 1000mg of sodium carbonate, and from about 125mg to about 1000mg of sodium bicarbonate.
15. (Cancelled).
16. (Cancelled).
17. (Cancelled).

18. (Cancelled).

19. (Cancelled).

20. (Cancelled).

21. (Cancelled).

22. (Cancelled).

23. (Cancelled).

24. (Cancelled).

25. (Cancelled).

26. (Cancelled).

27. (Cancelled).

28. (Cancelled).

29. (Cancelled).

30. (Cancelled).

31. (Cancelled).

32. (Cancelled).

33. (Cancelled).

34. (Cancelled).

35. (Cancelled).

36. (Cancelled).